The results showed that treatment did not influence the levels of Cyr61 in active patients (Supplementary Figure 2), so the change of Cyr61 after remission was mainly due to the improvement of the disease activity in AOSD patients. This evidence concerns the gene CCN1 and adult-onset Still disease.